Eli Lilly, compounding and Food and Drug Administration
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down on off-brand versions. Eli Lilly announced in a press release last week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback